RxDoctor Payments DataLook up a doctor →

Robert Kaner, MD

Pulmonary Disease · New York, NYNPI 1205923380

Payments from drug & device makers

$2,309,538in general payments, 2019–2025

Across 331 payments — averaging $6977.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2.1M
  • CSL Behring$79K
  • Boehringer Ingelheim International GmbH$75K
  • Chiesi USA, Inc.$25K
  • Genentech USA, Inc.$15K
  • United Therapeutics Corporation$12K
  • plus $17K from 7 others
$7,723in research payments, 2019–2025

Across 5 payments — averaging $1544.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$8K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,309,538 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$93,336
Medicare patients
336
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →